Value-based medicine and vitreoretinal diseases

Current Opinion in Ophthalmology

Volumn 15, Issue 3, 2004, Pages 167-172

  Brown, Melissa M ^a,b   Brown, Gary C ^a,b,c   Sharma, Sanjay ^a,d  

^a CENTER FOR VALUE BASED MEDICINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c WILLS EYE HOSPITAL   (United States)

^d Queens Medical College   (Canada)

Author keywords

Cost utility analysis; Utility analysis; Value based medicine

Indexed keywords

GANCICLOVIR;

COST UTILITY ANALYSIS; CRYOTHERAPY; ECONOMIC ASPECT; EVIDENCE BASED MEDICINE; FUNCTIONAL ASSESSMENT; GLAUCOMA; HEALTH CARE COST; HEALTH CARE QUALITY; HEALTH SERVICE; HUMAN; LIFE EXPECTANCY; LOW LEVEL LASER THERAPY; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUESTIONNAIRE; RETINA MACULA EDEMA; RETINITIS; RETINOPATHY; REVIEW; SUBRETINAL NEOVASCULARIZATION; VISION; VISUAL IMPAIRMENT; VITRECTOMY; VITREORETINOPATHY; VITREOUS HEMORRHAGE;

COST OF ILLNESS; COST-BENEFIT ANALYSIS; DELIVERY OF HEALTH CARE; EYE DISEASES; HEALTH CARE COSTS; HUMANS; QUALITY OF LIFE; RETINAL DISEASES; VITREOUS BODY;

EID: 2442476455     PISSN: 10408738     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.icu.0000120675.27548.d5     Document Type: Review

References (50)

1. National health expenditures. Aggregate and per capita amounts, percent distribution, and average annual percent growth, by source of funds: Select calendar years 1980-2001, From the Internet@cms.hhs.gov, cited 1-20-03.
2. National healthcare expenditures projections: 2001-2011. From the Internet@cms.hhs.gov, cited 1-01-04.
3. Brown MM, Brown GC, Sharma S, et al.: Physician manpower and health care expenditures in the United States: a thirty year perspective. J Healthcare Finance 2001, 27:55-64.
4. World Health Organization Report 2000. From the Internet@www.who.int/ health-systems-performance/whr2000.htm, cited 12-30-03.
5. Brown MM, Brown GC: Outcome of corneal transplantation. Value-based health care. Br J Ophthalmol 2002, 86:2-3.
6. Brown MM, Brown GC, Sharma S: Value-based medicine. Evidence-Based Eye Care 2002, 3:8-9.
7. Brown MM, Brown GC, Sharma S, et al.: Health care economic analyses and value-based medicine. Surv Ophthalmol 2003, 48:204-223. Comprehensive review article on cost-utility analyses, other healthcare economic analyses, and VBM.
8. Brown MM, Brown GC, Sharma S, et al.: Quality of life associated with visual loss. Time tradeoff utility analysis comparison with systemic health states. Ophthalmology 2003, 110:1076-1081.
9. Evidence-Based Medicine Working Group: A new approach to teaching the practice of medicine. JAMA 1992, 268:2420-2425.
10. Sackett DL, Straus SE, Richardson WS, et al.: Evidence-Based Medicine. How to Practice and Teach EBM. New York: Churchill Livingstone; 2000.
11. Sharma S: Levels of evidence and interventional ophthalmology. Can J Ophthalmol 1997, 32:359-362.
12. Steinberg EP, Tielsch JM, Schein OD, et al.: The VF-14. An index of functional impairment in patients with cataract. Arch Ophthalmol 1994, 112:630-638.
13. Mangione CM, Lee PP, Gutierrez PR, et al.: National Eye Institute Visual Function Questionnaire Field Test Investigators. Development of the 25-item National Eye Institute Visual Function Questionnaire. Arch Ophthalmol 2001, 119:1050-1058.
14. Brown GC, Brown MM, Sharma A: Value-Based Medicine. AMA Press, in press.
15. Redelmeier DA, Detsky A: A clinician's guide to utility measurement. Med Decis Making 1995, 22:271-281.
16. Drummond MF, O'Brien B, Stoddart GL, et al.: Methods for the Economic Evaluation of Health Care Programmes, Second Edition. New York: Oxford University Press, 1999:139-199.
17. Gold MR, Patrick DL, Torrance GW, et al.: Identifying and valuing outcomes. In Cost-Effectiveness in Health and Medicine. Edited by Gold ME, Siegel JE, Russell LB, et al. New York: Oxford University Press, 1996:82-134.
18. Brown GC: Vision and quality of life. Trans Am Ophthalmol Soc 1999, 97:473-512.
19. Brown GC, Brown MM, Sharma S, et al.: Utility values associated with age-related macular degeneration. Arch Ophthalmol 2000, 118:47-51.
20. Brown MM, Brown GC, Sharma S, et al.: Utility values and diabetic retinopathy. Am J Ophthalmol 1999, 128:324-330.
21. Hollands H, Lam M, Pater J, et al.: Reliability of the time trade-off technique of utility assessment in patients with retinal disease. Can J Ophthalmol 2001, 36:202-209.
22. Sharma S, Brown GC, Brown MM, et al.: Validity of the time trade-off and standard gamble methods of utility assessment in retinal patients. Br J Ophthalmol 2002, 86:493-496.
23. Brown GC, Brown MM, Sharma S, et al.: The reproducibility of ophthalmic utility values. Trans Am Ophthalmol Soc 2001, 99:71-76.
24. Brown GC, Brown MM, Sharma S, et al.: Quality of life associated with diabetes mellitus in an adult population. J Diab Comp 2000, 14:18-24.
25. Stein J, Brown GC, Brown MM, et al.: The quality of life of patients with hypertension. J Clin Hypertension 2002, 4:181-188.
26. Brown GC, Brown MM, Sharma S: Difference between ophthalmologist and patient perceptions of quality-of-life associated with age-related macular degeneration. Can J Ophthalmol 2000, 35:27-32.
27. Brown MM, Brown GC, Sharma S, et al.: Utility values associated with blindness in an adult population. Br J Ophthalmol 2001, 85:327-331.
28. Brown MM, Brown GC, Sharma S, et al.: Quality of life with visual acuity loss from diabetic retinopathy and age-related macular degeneration. Arch Ophthalmol 2002, 120:481-484.
29. Klarman H, Francis J, Rosenthal G: Cost-effectiveness applied to the treatment of chronic renal disease. Med Care 1968, 6:48-55.
30. Laupacis A, Feeny D, Detsky AS, et al.: How attractive does a new technology have to be to warrant adoption and utilization. Tentative guidelines for using clinical and economic evaluations. Can Med Assoc J 1992, 146:473-481.
31. Heudebert GR, Centor RM, Klapow JC, et al.: What is heartburn worth? A cost-utility analysis of management strategies. J Gen Intern Med 2000, 15:175-182.
32. Siegel JE, Weinstein MC, Russell LB, et al.: Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine. JAMA 1996, 276:1339-1341.
33. Brown GC, Brown MM, Sharma S, et al.: A cost-utility analysis of interventions for proliferative vitreoretinopathy. Am J Ophthalmol 2002, 133:365.
34. Sharma S, Hollands H, Brown GC, et al.: The cost-effectiveness of early vitrectomy for the treatment of vitreous hemorrhage in diabetic retinopathy. Curr Opin Ophthalmol 2001, 12:230-234.
35. Atebara N, Brown GC, Cater J: Efficacy of anterior chamber paracentesis and Carbogen in treating acute nonarteritic central retinal artery occlusion. Ophthalmology 1995, 102:2029-2034.
36. Brown GC, Brown MM, Sharma S, et al.: Cost-effectiveness of therapy for threshold retinopathy of prematurity. Pediatrics 1999, 104:e47.
37. Javitt JC, Canner JK, Sommer A: Cost effectiveness of current approaches to the control of retinopathy in type I diabetics. Ophthalmology 1989, 96:255-264.
38. Javitt JC, Canner JK, Frank RG, et al.: Detecting and treating retinopathy in patients with type I diabetes mellitus. A health policy model. Ophthalmology 1990, 97:483-494.
39. Javitt JC, Aiello LP: Cost-effectiveness of detecting and treating diabetic retinopathy. Ann Intern Med 1996, 124:164-169.
40. Brown GC, Brown MM, Sharma S, et al.: Incremental cost-effectiveness of laser photocoagulation for choroidal neovascularization associated with histoplasmosis. Retina 2000, 20:331-337.
41. Brown GC, Brown MM, Sharma S: Incremental cost-effectiveness of laser therapy for subfoveal choroidal neovascularization. Ophthalmology 2000, 107:1374-1380.
42. Brown GC, Brown MM, Sharma S, et al.: Incremental cost-effectiveness of therapeutic interventions for branch retinal vein occlusion. Ophthalmic Epidemiol 2002, 9:1-10.
43. Sharma S, Brown GC, Brown MM, et al.: The cost-effectiveness of grid laser photocoagulation for the treatment of diabetic macular edema: results of a patient-based cost-utility analysis. Curr Opin Ophthalmol 2000, 11:175-179.
44. Brown GC, Brown MM: Is prophylactic PRP in ischemic CRVO a good idea? Rev Ophthalmol 2000, 7:106, 108, 111.
45. Sharma S, Brown GC, Brown MM, et al.: The cost-effectiveness of photodynamic therapy for fellow eyes with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology 2001, 108:2051-2059.
46. Membreno J, Brown MM, Brown GC, et al.: A cost-utility analysis of therapy for amblyopia. Ophthalmology 2002, 109:2265-2271.
47. Busbee B, Brown MM, Brown GC, et al.: Incremental cost-effectiveness of initial cataract surgery. Ophthalmology 2002, 109:606-612.
48. Busbee BG, Brown MM, Brown GC, et al.: Cost-utility analysis of cataract surgery in the second eye. Ophthalmology 2003, 110:2310-2317. An excellent example of an ocular cost-utility analysis.
49. Braae R, McNee W, Moore D: Managing pharmaceutical expenditure while increasing access. The pharmaceutical management agency (PHARMAC) experience. Pharmacoeconomics 1999, 16:649-660.
50. Brown E, Fitzner K: Cost-effectiveness and coverage policy. Physician Exec 1999, 25:75-77.